Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Drug Profile

Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Alternative Names: Anti-CD123 CAR-T cells; Anti-CD38 CAR-T cells; Anti-HAVCR2 mAbs - Sorrento; Anti-PD-1 mAbs - Sorrento Therapeutics; Anti-PD-L1 mAbs - Sorrento Therapeutics; Anti-TIM3 mAbs- Sorrento Therapeutics; CAR-T - TNK Therapeutics; CAR-T c-KIT; CAR-T GD3; CAR-T IL13R; STI 1014; STI 1110; STI-A0168; STI-A020X; STI-A050X; STI-A060X; STI-A1010; STI-A1011; STI-A1012; STI-A1014; STI-A1110; T-007; T-009; ZKAB001

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC; Sorrento Therapeutics
  • Developer Sorrento Therapeutics; TNK Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors; Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists; Ganglioside inhibitors; HAVCR2 protein inhibitors; Interleukin 13 expression modulators; Interleukin 13 inhibitors; Interleukin-3-receptor-alpha-subunit-antagonists; Programmed cell death-1 ligand-1inhibitors; Programmed cell death-1 receptor antagonists; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Cancer; Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 22 Jun 2018 Zhaoke Pharmaceutical plans a phase I/II trial for ZKAB 001 for Osteosarcoma in China (ChiCTR1800016649)
  • 08 Mar 2018 Sorrento Pharma submits IND application for anti-CD38 CAR-T cell therapy
  • 31 Jan 2018 Lees Pharm and Sorrento Therapeutics plans a clinical trial for Cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top